Current Perspectives on Gynecologic Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 79
Special Issue Editor
Interests: epidemiology; genetics; meta-analysis; gynecologic cancer
Special Issue Information
Dear Colleagues,
Gynecologic cancers—encompassing malignancies of the cervix, ovaries, uterus, vulva, and vagina—remain a critical global health challenge, accounting for significant morbidity and mortality among women worldwide. Despite advancements in screening and treatment, these cancers persistently highlight disparities in access to care, variable therapeutic responses, and unmet needs in survivorship. This Special Issue, Current Perspectives on Gynecologic Cancers, seeks to illuminate the rapidly evolving landscape of research and clinical practice, offering a synthesis of cutting-edge discoveries, translational innovations, and multidisciplinary approaches that are reshaping the field.
Recent years have witnessed transformative progress in understanding the molecular underpinnings of gynecologic malignancies. Breakthroughs in genomic and epigenomic profiling have unraveled tumor heterogeneity, identified driver mutations (e.g., TP53, BRCA1/2, PIK3CA), and uncovered biomarkers predictive of treatment response or resistance. The rise of immunotherapy, particularly immune checkpoint inhibitors targeting PD-1/PD-L1 in cervical and endometrial cancers, has reinvigorated hope for patients with advanced or recurrent disease. Similarly, PARP inhibitors have become a cornerstone in managing BRCA-mutated ovarian cancer, while antibody-drug conjugates like mirvetuximab soravtansine offer precision targeting of folate receptor-alpha-positive tumors.
Equally groundbreaking are advances in early detection and prevention. Liquid biopsy technologies, including circulating tumor DNA (ctDNA) and exosome-based assays, now enable non-invasive monitoring of minimal residual disease and recurrence. Meanwhile, HPV vaccination campaigns and AI-enhanced cervical screening programs are driving progress in primary prevention. Beyond biology, the integration of artificial intelligence (AI) into diagnostic imaging, risk prediction models, and treatment planning exemplifies the fusion of technology and oncology. Furthermore, it highlights the role of the tumor microenvironment, microbiome interactions, and metabolic reprogramming in tumor progression, offering novel therapeutic targets.
By compiling reviews and original research, this collection underscores the importance of interdisciplinary collaboration—bridging oncology, genetics, bioengineering, and public health—to translate scientific discovery into equitable clinical practice. We invite readers to explore these contributions, which collectively aim to redefine standards of care and inspire future innovation in the fight against gynecologic cancers.
Dr. Kecheng Huang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecology
- genetics
- biology
- bioinformatics
- review
- predictive model
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
